Development and application of angiography technology using carbon dioxide as contrast agent
10.7659/j.issn.1005-6947.250139
- VernacularTitle:以二氧化碳为造影剂的血管造影技术的发展与应用
- Author:
Nan HE
1
;
Yiwei LIU
;
Qingqing LI
;
Xiaobin TANG
;
Sheng WANG
;
Zhong CHEN
Author Information
1. 首都医科大学附属北京安贞医院 血管外科,北京 100029
- Publication Type:Journal Article
- Keywords:
Angiography;
Contrast Media;
Carbon Dioxide;
Review
- From:
Chinese Journal of General Surgery
2025;34(6):1262-1274
- CountryChina
- Language:Chinese
-
Abstract:
Carbon dioxide(CO2),a colorless,odorless,low-density negative contrast agent with no nephrotoxicity or allergic reactions,has seen increasingly widespread application in the field of vascular imaging in recent years,particularly in patients with iodine allergy or renal insufficiency.When combined with digital subtraction angiography,CO2 angiography has demonstrated high-quality imaging in various arterial and venous sites such as the abdominal aorta,renal arteries,iliac arteries,lower limb arteries,and inferior vena cava.It has also shown safety and efficacy in clinical scenarios such as peripheral arterial disease,dialysis access evaluation,and transjugular intrahepatic portosystemic shunt procedures.This review systematically summarizes domestic and international research progress on CO2 angiography,outlines its physicochemical properties,injection dosages and parameters,clinical indications,and imaging characteristics,and compares its image quality with that of iodine-based contrast agents.Common complications,their mechanisms,and preventive measures are also discussed.Although the image quality of CO2 is slightly inferior to that of iodine agents,it remains sufficient for most diagnostic and therapeutic needs,with a low overall incidence of mainly mild and transient adverse effects.With the development of automated injection systems and digital variance angiography technology,CO2 imaging quality is expected to continue improving,and its application scope is likely to expand further.Future efforts should focus on strengthening multicenter clinical research and establishing standardized operational protocols to promote the broader adoption and regulated use of this technology.
